Drugmakers that complain about the growing cost to bring new molecular entities to market aren’t exaggerating, according to a study released last month by the Tufts Center for the Study of Drug Development (CSDD). Even with the initiation of mechanisms to speed drug development such as breakthrough therapy designation and accelerated review, developing a medicine [...]
http://www.fiercepharma.com/story/takedas-us-chief-bows-out-amid-management-shake/2014-11-25?utm_medium=nl&utm_source=internal Takeda Chief is out, EVP Lise Kingo at Novo is out, Allergan pruning the Executive offices, plenty of others. All the M&A buys pipelines, but surely does not guarantee FDA follow through. www.studyops.com
Karla Burke Life Sciences Senior Marketing Specialist at Thomson ReutersTop Contributor Leading health experts said that having decided it is ethical to use non-approved products to help deal with the Ebola virus epidemic, it would be unethical if those drugs were administered in the context of randomized clinical trials. “No one insisted Western medical workers [...]
